Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nasdaq Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.81 (market cap $39.89B), while Nasdaq Inc trades at $88.21 (market cap $49.81B). The key difference: Nasdaq Inc is the larger of the two by market cap, and Nasdaq Inc pays a 1.27% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NDAQ | |
|---|---|---|
Market Cap | $39.89B | $49.81B |
Sector | Health | Financials |
52-Week High | $491.22 | $100.98 |
52-Week Low | $278.09 | $76.85 |
Enterprise Value | $38.15B | $56.88B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Nasdaq (NDAQ) trades at $88.08, up 0.64% today, with a bullish technical signal and strong earnings momentum after beating EPS estimates for three consecutive quarters. Revenue grew to $8.26 billion in 2025, with net income margin expanding to 23.03%. The stock shows robust institutional support, with 61% of analysts rating it a Buy and a consensus price target of $105.60, indicating ~20% upside potential.
Outlook remains positive given Nasdaq's dominant market position and exposure to capital markets growth, though risks include high valuation multiples (P/E 26.53) and sensitivity to equity market volatility. The stock's recent strength near resistance at $89 may prompt consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
